[1] Ponsioen CY, Lindor KD, Mehta R, et al. Design and endpoints for clinical trials in primary sclerosing cholangitis. Hepatology, 2018, 68: 1174-1188.
[2] 张建军, 冯少春. 血浆置换联合血液灌流治疗原发性硬化性胆管炎的临床研究. 第一届全国疑难重型肝病大会、第四届全国人工肝及血液净化学术年会, 中国江西南昌, 2008.
[3] 李冰, 张健, 邵清, 等. 内镜介入治疗原发性硬化性胆管炎的临床效果研究中华全科医学, 2013, 11: 1716-1717.
[4] Vleggaar FP, Monkelbaan JF, Van Erpecum KJ. Probiotics in primary sclerosing cholangitis: A randomized placebo-controlled crossover pilot study. Eur J Gastroen Hepat, 2008, 20: 688-692.
[5] Hommes DW, Erkelens W, Ponsioen C, et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol, 2008, 42: 522‐526.
[6] Cullen SN, Rust C, Fleming K, et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol, 2008, 48: 792-800.
[7] Lindor KD, Kowdley KV, Luketic VaC, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology, 2009, 50: 808-814.
[8] Tabibian JH, Weeding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther, 2013, 37: 604-612.
[9] Lindström L, Hultcrantz R, Boberg KM, et al. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol, 2013, 11: 841‐846.
[10] Rahimpour S, Nasiri-Toosi M, Khalili H, et al. A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study. J Gastrointestin Liver Dis, 2016, 25: 457-464.
[11] Trauner M, Fickert P, Hirschfield G, et al. Norursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis: results of a phase II dose finding study. J Hepatol, 2016, 64: S208-S209.
[12] Fickert P, Hirschfield GM, Denk G, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol, 2017, 67: 549-558.
[13] Ponsioen CY, Chapman RW, Chazouilleres O, et al. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. Hepatology, 2016, 63: 1357-1367.
[14] Ponsioen CY, Lam K, Van Milligen De Wit AW, et al. Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol, 1999, 94: 2403-2407.
[15] Al Mamari S, Djordjevic J, Halliday JS, et al. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol, 2013, 58: 329-334.
[16] Tischendorf JJW, Hecker H, Krüger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol, 2007, 102: 107-114.
[17] Rosselli M, Macnaughtan J, Jalan R, et al. Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut, 2013, 62: 1234-1241.
[18] Sheehan M, Haythorn P. Predictive values of various liver function tests with respect to the diagnosis of liver disease. Clin biochem, 1979, 12: 262-263.
[19] Corpechot C, Gaouar F, El Naggar A, et al. Baseline Values and Changes in Liver Stiffness Measured by Transient Elastography Are Associated With Severity of Fibrosis and Outcomes of Patients With Primary Sclerosing Cholangitis. Gastroenterology, 2014, 146: 970-979.
[20] Ruiz A, Lemoinne S, Carrat F, et al. Radiologic course of primary sclerosing cholangitis: Assessment by three‐dimensional magnetic resonance cholangiography and predictive features of progression. Hepatology, 2014, 59: 242-250. |
